AstraZeneca PLC (AZN)vsProtagonist Therapeutics Inc (PTGX)
AZN
AstraZeneca PLC
$185.95
-0.79%
HEALTHCARE · Cap: $282.69B
PTGX
Protagonist Therapeutics Inc
$97.38
-5.26%
HEALTHCARE · Cap: $6.10B
Smart Verdict
WallStSmart Research — data-driven comparison
AstraZeneca PLC generates 81505% more annual revenue ($60.44B vs $74.06M). AZN leads profitability with a 17.2% profit margin vs -154.9%. AZN earns a higher WallStSmart Score of 64/100 (C+).
AZN
Buy64
out of 100
Grade: C+
PTGX
Hold38
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+8.2%
Fair Value
$194.77
Current Price
$185.95
$8.82 discount
Intrinsic value data unavailable for PTGX.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 22 in profit
Strong operational efficiency at 27.9%
Generating 1.8B in free cash flow
Revenue surging 99.0% year-over-year
Earnings expanding 351.3% YoY
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Areas to Watch
Moderate valuation
Distress zone — elevated risk
Trading at 9.5x book value
Weak financial health signals
ROE of -17.5% — below average capital efficiency
Negative free cash flow — burning cash
Comparative Analysis Report
WallStSmart ResearchBull Case : AZN
The strongest argument for AZN centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 17.2% and operating margin at 27.9%. Revenue growth of 12.5% demonstrates continued momentum.
Bull Case : PTGX
The strongest argument for PTGX centers on Revenue Growth, EPS Growth, Debt/Equity. Revenue growth of 99.0% demonstrates continued momentum.
Bear Case : AZN
The primary concerns for AZN are P/E Ratio, Altman Z-Score.
Bear Case : PTGX
The primary concerns for PTGX are Price/Book, Piotroski F-Score, Return on Equity.
Key Dynamics to Monitor
AZN profiles as a mature stock while PTGX is a hypergrowth play — different risk/reward profiles.
PTGX carries more volatility with a beta of 1.88 — expect wider price swings.
PTGX is growing revenue faster at 99.0% — sustainability is the question.
AZN generates stronger free cash flow (1.8B), providing more financial flexibility.
Bottom Line
AZN scores higher overall (64/100 vs 38/100), backed by strong 17.2% margins and 12.5% revenue growth. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AstraZeneca PLC
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AstraZeneca PLC discovers, develops, manufactures and markets prescription drugs in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infections, neuroscience and gastroenterology worldwide. The company is headquartered in Cambridge, the United Kingdom.
Protagonist Therapeutics Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Protagonist Therapeutics, Inc., a clinical-stage biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address unmet medical needs. The company is headquartered in Newark, California.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?